Chengfeng Miao1, Hanbin Chen2, Yulian Li1, Ying Guo1, Feifei Xu3, Qi Chen1, Yanyan Zhang1, Mengjun Hu4, Guorong Chen5. 1. Department of Pathology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, PR China. 2. Department of Radiation Oncology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, PR China. 3. Department of Pathology, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, PR China. 4. Department of Pathology, Zhuji People's Hospital, Shaoxing, Zhejiang, PR China. hu-menjun@163.com. 5. Department of Pathology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, PR China. chengr1978@sina.com.
Abstract
BACKGROUND: Diabetic encephalopathy is a severe diabetes complication with cognitive dysfunction and neuropsychiatric disability. The mechanisms underlying diabetic encephalopathy is believed to be relevant with oxidative stress, vascular amylin deposition, immune receptors, inflammation, etc. This study wanted to evaluate the ability of curcumin and its analog A13 to alleviate oxidative stress and inflammation in diabetes-induced damages in brain. METHODS: Sixty adult male Sprague-Dawley rats were divided into 5 groups: normal control (NC) group, diabetes mellitus (DM) group, curcumin-treated diabetes mellitus (CUR) group, high dose of A13-treated diabetes mellitus (HA) group, low dose of A13-treated diabetes mellitus (LA) group. Activation of the nuclear factor kappa-B (NF-κB p65) pathway was detected by RT-qPCR, immunohistochemical (IHC) staining and Western blot; oxidative stress was detected by biochemical detection kit; brain tissue sections were stained with hematoxylin-eosin (HE) staining and Myelin staining. RESULTS: RT-qPCR, IHC staining and Western blot showed that curcumin and A13 treatment could inhibit the NF-κB p65 pathway. Curcumin and A13 increased the activity of superoxide dismutase and decreased the malondialdehyde level in the brain of diabetic rats. Furthermore, HE staining and Myelin staining demonstrated that the histological lesions of the brain in diabetic rats could be significantly ameliorated by curcumin and A13. CONCLUSION: Curcumin analog A13 could alleviate the damages in the brain of diabetes rats by regulating the pathways of inflammation and oxidative stress. A13 may be a new potential therapeutic agent for diabetic encephalopathy.
BACKGROUND:Diabetic encephalopathy is a severe diabetes complication with cognitive dysfunction and neuropsychiatric disability. The mechanisms underlying diabetic encephalopathy is believed to be relevant with oxidative stress, vascular amylin deposition, immune receptors, inflammation, etc. This study wanted to evaluate the ability of curcumin and its analog A13 to alleviate oxidative stress and inflammation in diabetes-induced damages in brain. METHODS: Sixty adult male Sprague-Dawley rats were divided into 5 groups: normal control (NC) group, diabetes mellitus (DM) group, curcumin-treated diabetes mellitus (CUR) group, high dose of A13-treated diabetes mellitus (HA) group, low dose of A13-treated diabetes mellitus (LA) group. Activation of the nuclear factor kappa-B (NF-κB p65) pathway was detected by RT-qPCR, immunohistochemical (IHC) staining and Western blot; oxidative stress was detected by biochemical detection kit; brain tissue sections were stained with hematoxylin-eosin (HE) staining and Myelin staining. RESULTS: RT-qPCR, IHC staining and Western blot showed that curcumin and A13 treatment could inhibit the NF-κB p65 pathway. Curcumin and A13 increased the activity of superoxide dismutase and decreased the malondialdehyde level in the brain of diabeticrats. Furthermore, HE staining and Myelin staining demonstrated that the histological lesions of the brain in diabeticrats could be significantly ameliorated by curcumin and A13. CONCLUSION:Curcumin analog A13 could alleviate the damages in the brain of diabetesrats by regulating the pathways of inflammation and oxidative stress. A13 may be a new potential therapeutic agent for diabetic encephalopathy.
Authors: Han Ly; Nirmal Verma; Fengen Wu; Miao Liu; Kathryn E Saatman; Peter T Nelson; John T Slevin; Larry B Goldstein; Geert Jan Biessels; Florin Despa Journal: Ann Neurol Date: 2017-07-29 Impact factor: 10.422
Authors: Wilma Helena Oliveira; Ana Karolina Nunes; Maria Eduarda Rocha França; Laise Aline Santos; Deniele Bezerra Lós; Sura Wanessa Rocha; Karla Patrícia Barbosa; Gabriel Barros Rodrigues; Christina Alves Peixoto Journal: Brain Res Date: 2016-05-10 Impact factor: 3.252
Authors: María L Del Prado-Audelo; Isaac H Caballero-Florán; Jorge A Meza-Toledo; Néstor Mendoza-Muñoz; Maykel González-Torres; Benjamín Florán; Hernán Cortés; Gerardo Leyva-Gómez Journal: Biomolecules Date: 2019-02-08